New Zealand’s Fisher & Paykel Healthcare hikes 2027 profit guidance

Fisher & Paykel Healthcare Corporation has increased its profit outlook for the year 2027 and provided a positive forecast for the first half of the year. The medical device manufacturer has predicted first-half revenue of around NZ$1.24 billion and net profit after tax of approximately NZ$280 million, reflecting a 14% increase in operating revenue and a 24% rise in net profit compared to the previous year.

Managing Director and CEO Lewis Gradon highlighted a strong start to the first half, particularly in the Hospital product group, fueled by sustained demand for their latest hardware devices and evolving clinical practices boosting consumable sales. For the entire 2027 fiscal year, Fisher & Paykel has expanded its net profit after tax guidance to a range of NZ$525 million to NZ$565 million, up from the earlier range of NZ$500 million to NZ$550 million announced in May.

Additionally, the company has marginally increased its operating revenue forecast to a range of NZ$2.47 billion to NZ$2.57 billion, from the earlier range of NZ$2.45 billion to NZ$2.57 billion. The news of the improved guidance led to a rise in Fisher & Paykel shares by over 1% in both Australian and New Zealand markets.